Roche Keeps Lifecycle Management In Motion For Oncology Portfolio
Executive Summary
The potential near-term approval of Roche/Genentech's Herceptin (trastuzumab) for adjuvant treatment of early-stage, HER2-positive breast cancer is one of several line extensions under the firms' aggressive lifecycle management of their partnered oncologics
You may also be interested in...
Avastin Ovarian Cancer Approval Brings Some Clarity On PFS Endpoint
New claim for platinum-resistant recurrent disease based on a median 3.4-month improvement in progression-free survival – with favorable trends in overall survival, overall response rate and duration of response – confirms agency’s willingness to entertain a progression endpoint in this tumor type.
Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use
FDA approves use of Genentech’s bevacizumab for second-line treatment of metastatic colorectal cancer patients who have progressed on a first-line, Avastin-containing chemotherapeutic regimen.
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy